ChromaDex, Inc.

234 articles about ChromaDex, Inc.

• 

  Biopharma Update on the Novel Coronavirus: October 6

  10/6/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.

• New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice

  9/9/2020

  Preclinical study at Emory University explores relationship between cellular NAD+ and retinal damage

• ChromaDex to Present at the LD 500 Virtual Investor Conference

  8/26/2020

  ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at the LD 500 investor conference.

• New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients

  8/18/2020

  Niagen® (patented nicotinamide riboside) may reduce production of inflammatory cytokines in pilot study of Stage D heart failure patients

• ChromaDex Corporation Reports Second Quarter 2020 Financial Results

  8/6/2020

  “We achieved record net sales of $15.3 million in the second quarter while maintaining our focus on the science, announcing our 200th research agreement and tenth published human trial on Niagen®,” says ChromaDex CEO Rob Fried.

• New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism

  7/16/2020

  First-of-its-kind preclinical study shows that Niagen® resolves social deficits and anxiety-like behaviors in male mice

• ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research

  7/14/2020

  ChromaDex R&D program continues to pioneer NAD+ and Niagen® research and inks over 200 external research collaborations

• ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

  7/9/2020

  Dr. Charles Brenner and a team of scientists from three US universities find that Niagen® decreases Coronavirus replication in animal cells

• 

  Biopharma Update on the Novel Coronavirus: July 8

  7/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.

• ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models

  7/7/2020

  Study on ChromaDex’s NR ingredient to be conducted at NIH-NIAID’s Rocky Mountain Labs, one of the few Biosafety Level 4 labs in the U.S.

• New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage

  6/30/2020

  ChromaDex shares new preclinical and clinical findings revealing potential of Niagen® across a variety of health conditions, paving the way for further clinical research

• ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation

  6/17/2020

  ChromaDex quality control and R&D facility in Longmont, Colorado obtains ISO/IEC 17025:2017 Accreditation

• ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference

  6/16/2020

  ChromaDex Corp. is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 2:00pm ET.

• First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)

  6/3/2020

  New research from Dr. Charles Brenner expands human conditions with disturbed NAD systems including alcohol-related liver disease and other liver diseases.

• ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting

  6/1/2020

  ChromaDex Corp. announced it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide in Human Health and Disease: The State of the Science on Nutrition Interventions” tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted by the American Society for Nutrition.

• ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN)

  5/27/2020

  ChromaDex joins industry leaders to discuss “What New Dietary Ingredient Master Files Mean for Innovation & Compliance”

• ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition

  5/21/2020

  ChromaDex Corp. announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition and its Foundation.

• Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)

  5/6/2020

  ChromaDex highlights additional clinical and preclinical research strengthening science and understanding behind Niagen®

• ChromaDex to Report First Quarter 2020 Financial Results on Monday, May 11, 2020

  5/1/2020

  ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor confere

• ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR)

  4/20/2020

  Preclinical research from Dr. Charles Brenner and a team of leading scientists from three US universities concludes that key steps in coronavirus infection and innate immunity involve a tug-of-war with cellular NAD